type here...
type here...
START FREE TRIAL

Healthcare

Technology & AIHealthcareM&AConsumer & RetailEnergyMiscellaneous

Qiagen Just Dropped Two Magic Words—And Wall Street Heard “Buyout”

Healthcare Ishan Majumdar -
Qiagen (NYSE:QGEN) just did the thing companies do right before Wall Street starts whispering louder. On March 2, CEO Thierry Bernard said the firm...

Is Merck’s HIV Win Really About Keytruda?

Healthcare Ishan Majumdar -
When Merck & Co. (NYSE:MRK) reported Phase 3 data showing its two-drug HIV regimen of doravirine and islatravir matched the efficacy of Gilead Sciences’...
spot_imgspot_img

Did Novo Nordisk’s Trial Miss Just Hand Lilly The Edge?

Healthcare Ishan Majumdar -
It has been a bruising few weeks for Novo Nordisk (NYSE:NVO). First came the clinical disappointment: CagriSema, the company’s...

Did Moderna’s Flu Rejection Signal A Deeper FDA SHIFT?

Healthcare Ishan Majumdar -
Moderna’s seasonal flu vaccine application was refused review by the FDA, triggering an immediate stock decline. The agency issued...

Hims & Hers Just Went Big on Cancer—But the DOJ Is Watching

Healthcare Ishan Majumdar -
Hims & Hers used the Super Bowl stage to push its latest offering: a $689 early cancer detection test....

Pfizer Takes On Eli Lilly & Novo: Who Gets OUTPLAYED in the Obesity Arms Race?

Healthcare Ishan Majumdar -
Pfizer just released mid-stage data from its Metsera-acquired obesity drug showing 12.3% weight loss at 28 weeks with monthly...

UnitedHealth CRASHES After Shocking Medicare Ruling — The Fallout Explained!

Healthcare Ishan Majumdar -
When a 0.09% number sends $96 billion out the window, you know something serious just happened. On January 27,...

Boston Scientific Penumbra Acquisition: The $15 Billion Gamble That Could Dominate Neurovascular Markets

Healthcare Ishan Majumdar -
If you're wondering what Boston Scientific (NYSE:BSX) has been up to lately, buckle up. On January 15, the medtech...
Load more

Qiagen Just Dropped Two Magic Words—And Wall Street Heard “Buyout”

Healthcare Ishan Majumdar -
Qiagen (NYSE:QGEN) just did the thing companies do right before Wall Street starts whispering louder. On March 2, CEO...

Is Merck’s HIV Win Really About Keytruda?

Healthcare Ishan Majumdar -
When Merck & Co. (NYSE:MRK) reported Phase 3 data showing its two-drug HIV regimen of doravirine and islatravir matched...

Did Novo Nordisk’s Trial Miss Just Hand Lilly The Edge?

Healthcare Ishan Majumdar -
It has been a bruising few weeks for Novo Nordisk (NYSE:NVO). First came the clinical disappointment: CagriSema, the company’s...

Did Moderna’s Flu Rejection Signal A Deeper FDA SHIFT?

Healthcare Ishan Majumdar -
Moderna’s seasonal flu vaccine application was refused review by the FDA, triggering an immediate stock decline. The agency issued...

Hims & Hers Just Went Big on Cancer—But the DOJ Is Watching

Healthcare Ishan Majumdar -
Hims & Hers used the Super Bowl stage to push its latest offering: a $689 early cancer detection test....

Pfizer Takes On Eli Lilly & Novo: Who Gets OUTPLAYED in the Obesity Arms Race?

Healthcare Ishan Majumdar -
Pfizer just released mid-stage data from its Metsera-acquired obesity drug showing 12.3% weight loss at 28 weeks with monthly...

UnitedHealth CRASHES After Shocking Medicare Ruling — The Fallout Explained!

Healthcare Ishan Majumdar -
When a 0.09% number sends $96 billion out the window, you know something serious just happened. On January 27,...

Boston Scientific Penumbra Acquisition: The $15 Billion Gamble That Could Dominate Neurovascular Markets

Healthcare Ishan Majumdar -
If you're wondering what Boston Scientific (NYSE:BSX) has been up to lately, buckle up. On January 15, the medtech...

AbbVie Trump Investment Deal: How Medicaid Cuts Bought Regulatory Peace!

Healthcare Ishan Majumdar -
AbbVie (NYSE:ABBV) just made a bold move—and the stakes are massive. The company agreed to invest $100 billion into...

Merck Revolution Medicines Acquisition: The $30 Billion Pipeline Gamble That Could Pay Off

Healthcare Ishan Majumdar -
Merck (NYSE:MRK) is making headlines again, this time for reportedly circling Revolution Medicines (NASDAQ:RVMD) in what could be one...

Niagen NR Patent Acquisition Unlocks Massive Pharma Potential—But There’s a Catch!

Healthcare Ishan Majumdar -
If you blinked, you may have missed one of the more intriguing biotech moves of the year. Niagen Bioscience...

BioMarin Amicus Acquisition: A $4.8 Billion Bet on Rare Disease Domination

Healthcare Ishan Majumdar -
BioMarin Pharmaceutical (NASDAQ:BMRN) just made its boldest move in years—unveiling a $4.8 billion all-cash acquisition of Amicus Therapeutics. The...
Load more

Baptista Research is a financial research house focused on the U.S. markets. We cover the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms.

Company

Headlines

Trump Wants Allies’ Help For Hormuz — THESE Stocks May React Next!

0
The Iran war has turned a narrow shipping corridor...

Progress Software Might Be The “Boring” Tech Stock Private Equity Loves Most

0
Rumors have been circulating around Progress Software (NASDAQ:PRGS). Some...

The $40 Billion Parenting Arms Race Is Powering Dick’s Sporting Goods!

0
Walk into a youth baseball tournament today and something...

Is Tesla Quietly Building A Utility Business Behind Its EV Brand?

0
Most people still think of Tesla (NASDAQ:TSLA) as a...

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2026 Baptista Research. All rights reserved.